Fecal calprotectin as a predictor of histological remission in patients with ulcerative colitis treated with vedolizumab: A retrospective cohort study

被引：0
|
作者：
Rubtsov, D. [1 ]
Ramaswamy, P. Kakkadasam [1 ]
Mohsen, W. [1 ]
机构：
[1] Gold Coast Univ Hosp, Gold Coast, Qld, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2021年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
66
引用
收藏
页码：104 / 104
页数：1
相关论文
共 50 条
  • [1] Calprotectin at week 12 is a predictor for histological remission in ulcerative colitis patients treated with Vedolizumab
    Rubstov, D.
    Ramaswamy, P. Kakkadasam
    Edwards, J.
    Shukla, D.
    Willmann, L.
    Moattar, H.
    Bhullar, M.
    Ishaq, N.
    Dorrington, A.
    Mohsen, W.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S515 - S516
  • [2] Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis
    Wing Yan Mak
    Anthony Buisson
    Michael J. Andersen
    Donald Lei
    Joel Pekow
    Russell D. Cohen
    Stacy A. Kahn
    Bruno Pereira
    David T. Rubin
    Digestive Diseases and Sciences, 2018, 63 : 1294 - 1301
  • [3] Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis
    Mak, Wing Yan
    Buisson, Anthony
    Andersen, Michael J., Jr.
    Lei, Donald
    Pekow, Joel
    Cohen, Russell D.
    Kahn, Stacy A.
    Pereira, Bruno
    Rubin, David T.
    DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (05) : 1294 - 1301
  • [4] FECAL CALPROTECTIN IS AN EARLY PREDICTOR OF ENDOSCOPIC RESPONSE AND HISTOLOGICAL REMISSION AFTER THE START OF VEDOLIZUMAB
    Pauwels, Renske W.
    de Vries, Annemarie C.
    Goet, Jorn
    Erler, Nicole S.
    Van der Woude, Christien Janneke
    GASTROENTEROLOGY, 2019, 156 (06) : S110 - S110
  • [5] Deep Remission As a Predictor of Clinical Outcomes in Vedolizumab-Treated Patients With Ulcerative Colitis
    Sandborn, William
    Colombel, Jean-Frederic
    Panaccione, Remo
    Lasch, Karen
    Mody, Reema
    Green, Alexandra
    Abhyankar, Brihad
    GASTROENTEROLOGY, 2015, 148 (04) : S256 - S256
  • [6] Deep remission as a predictor of clinical outcomes in vedolizumab-treated patients with ulcerative colitis
    Sandborn, W.
    Colombel, J. -F.
    Panaccione, R.
    Lasch, K.
    Mody, R.
    Green, A.
    Abhyankar, B.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S299 - S300
  • [7] Beyond Histological Remission: Intramucosal Calprotectin as a Potential Predictor of Outcomes in Ulcerative Colitis
    Guirgis, Marianne
    Wendt, Emily
    Wang, Lai Mun
    Walsh, Alissa
    Burger, Daniel
    Bryant, Robert V.
    Kent, Alex
    Adamson, Rebecca
    Brain, Oliver
    Travis, Simon P. L.
    Keshav, Satish
    JOURNAL OF CROHNS & COLITIS, 2017, 11 (04): : 460 - 467
  • [8] Comparison of histological activity in patients with ulcerative colitis in clinical remission with versus without elevated fecal calprotectin
    Botina, A.
    Shchukina, O.
    Kondrashina, E.
    Markova, E.
    Orlov, O.
    VIRCHOWS ARCHIV, 2013, 463 (02) : 203 - 203
  • [9] Low Fecal Calprotectin Predicts Histological Healing in Patients with Ulcerative Colitis with Endoscopic Remission and Leads to Prolonged Clinical Remission
    Kawashima, Kousaku
    Oshima, Naoki
    Kishimoto, Kenichi
    Kataoka, Masatoshi
    Fukunaga, Mai
    Kotani, Satoshi
    Sonoyama, Hiroki
    Oka, Akihiko
    Mishima, Yoshiyuki
    Kazumori, Hideaki
    Ishikawa, Noriyoshi
    Araki, Asuka
    Ishihara, Shunji
    INFLAMMATORY BOWEL DISEASES, 2023, 29 (03) : 359 - 366
  • [10] Faecal Calprotectin as a predictor of endoscopic and histologic remission in patients with Ulcerative Colitis
    Hahn, G. Drugg
    Flores, C.
    Afif, W.
    Wild, G.
    Bitton, A.
    Lakatos, P. L.
    Bessissow, T.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I843 - I844
12345